Live Breaking News & Updates on Disease progression
Stay updated with breaking news from Disease progression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.
Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.
A single-institutional cohort study found that in patients with melanoma, regressive status could be used as a valuable predictive marker of prognosis and response to systemic therapy.
This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.
The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.
Tai chi could help slow Parkinson's disease progression knowridge.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from knowridge.com Daily Mail and Mail on Sunday newspapers.